期刊文献+

三阴性乳腺癌中MMP9和P53的表达与其预后的关系研究 被引量:7

Research on the Correlation of MMP9 and P53 Expression with the Prognosis of Triple Negative Breast Cancer
原文传递
导出
摘要 目的:研究三阴性乳腺癌(triple negative breast cancer,TNBC)中基质金属蛋白酶9(matrix metal proteinase 9,MMP9)和P53的表达及其与三阴性乳腺癌预后的关系。方法:收集2002年3月至2011年7月上海交通大学医学院附属新华医院普外科诊治且临床资料完整的TNBC标本147例,通过免疫组化检测其MMP9、P53的表达。结合临床随访数据,分析MMP9、P53的表达与TNBC预后的关系。结果:TNBC占同期本院收治的乳腺癌13.3%(147/1103)。MMP9、P53在TNBC中的阳性表达率分别为47.6%和66.0%。MMP9与TNBC患者的淋巴结转移数显著相关(P=0.003)。MMP9表达阳性的TNBC与MMP9表达阴性TNBC患者60个月的无病生存(disease free survival,DFS)率分别为62%和83%,差异具有统计学意义(P=0.001);总体生存率(overall survival,OS)率分别为66%和73%,差异具有统计学意义(P=0.022)。P53表达阳性的TNBC和P53表达阴性的TNBC患者60个月的DFS分别为65%和87%(P=0.010);OS分别为60%和85%(P=0.005)。MMP9和P53的HR分别为3.353(95%CI:1.614-6.966,P=0.001)和2.979(95%CI:1.239-7.165,P=0.015)。结论:MMP9和P53在TNBC中的阳性表达与患者的预后不良有关,且MMP9为影响TNBC患者预后的独立危险因素。 Objective: To investigate the expression of MMP9 (matrix metal proteinase 9, MMP9) and P53 in TNBC (triple negative breast cancer, TNBC) ,and their relationship with the prognosis of TNBC. Methods: 147 cases of TNBC Paraffin specimens with complete clinical data which were treated in General Surgery Department, Affiliated Xinhua Hospital of Shanghai Jiaotong from March 2002 to July 2011 were collected. Expression of MMP9 and P53 were detected by immunohistochemistry. Combined with clinical follow-up data, the relationship between expression of MMP9/P53 and TNBC prognosis was studied. Results: In 1103 cases of breast cancer, 147 cases were TNBC (13.3%). The positive expression rate of MMP9 and P53 in TNBC were 47.6% and 66.0% respectively. MMP9 expression was associated with the number ofmetastasizing lymph nodes (P=0.003). The 60 months DFS (disease free survival rate) of TNBC patients with positive and negative MMP9 expression were 62% and 83% respectively,(P=0.001) and OS (Overall survival rate) were 66% and 73%(P=0.022). The 60 months DFS of TNBC patients with positive and negative P53 expression were 65% and 87% respectively (P=0.010), and OS were 60% and 85%(P=0.005). The hazard ratio of metastasis or recurrence for the status of MMP9 and P53 were 3.353 (95%CI: 1.614-6.966, P=0.001) and 2.979 (95%CI:1.239-7.165,P=0.015) respectively. Conclusion: The upregulation of MMP9 and P53 expression were associated with the poor prognosis of patients with TNBC, and MMP9 was an independent risk factor. high expression of MMP9 and P53 indicated poor prognosis in TNBC.
出处 《现代生物医学进展》 CAS 2014年第5期881-884,共4页 Progress in Modern Biomedicine
基金 国家自然科学基金青年科学基金项目(81102016)
关键词 基质金属蛋白酶9 P53 三阴性乳腺癌 预后 MMP9 P53 Triple negative breast cancer Prognosis
  • 相关文献

参考文献20

  • 1Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative br- east cancer[J]. Clin Cancer Res, 2013, 19(23):6380-6388.
  • 2Mahamodhossen YA, Liu W, Rong-Rong Z. Triple-negative breast ca- ncer: new perspectives for novel therapies[J]. Med Oncol, 2013, 30(3): 653-658.
  • 3Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression:comparison of clinicopathologic features and survival[J]. Clin Med Res,2009,7(1-2):4-13.
  • 4Lin C, Chien SY, Chen LS, et al. Triple negative breast carcinoma is a prognostic factor in Taiwan Residents women[J]. BMC Cancer, 2009, (9): 192 -201.
  • 5Mersin H, Yildirim E, Berberoglu U, et al. The prognostic importance of triple negative breast carcinoma[J]. Breast., 2008, 17(4):341-346.
  • 6Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA[J]. Breast Cancer Res Treat,2009,113(2):357-370.
  • 7Wu K, Huang S, Zhu M, et al. Expression of synuclein gamma indica- tes poor prognosis of triple-negative breast cancer [J]. Med Oncol, 2013, 30(3):612-618.
  • 8Parinyanitikul N, Blumenschein GR, Wu Y, et al. Mesothelin Express- ion and Survival Outcomes in Triple Receptor Negative Breast Cancer [J], Clin Breast Cancer, 2013 Jun 27.
  • 9Neuman HB, Weiss JM, Sehrag D, et al. Patient demographic and tum- or characteristics influencing oncologist follow-up frequency in older breast cancer survivors[J]. Ann Surg Oncol, 2013, 20(13):4128-4136.
  • 10Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug dev- elopment and approval in breast cancer[J]. Clin Cancer Res, 2013, 19(23):6360-6370.

同被引文献91

  • 1王燕.p53对三阴性乳腺癌预后的意义及与铂类化疗药物敏感性的关系[J].中国老年学杂志,2014,34(7):1804-1805. 被引量:4
  • 2Parkin DM, Bray F, Felay J, et al. Global cancer statistics, 2002 [ J ]. CA cancer J clin,2005,55 (2) :74-108.
  • 3Foulkes WD, Smith IE, Reis-Filho JS, et al. Triple-negative tumors [J]. N Engl J Med,2010,363(20) :1938-1948.
  • 4Carey LA,Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study E J 1. JAMA, 2006, 295 (21) :2492-2502.
  • 5Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemieal and clini- cal characterization of the basal-like subtype of invasive breast carci- noma[ J ]. Clin Cancer Res ,2004,10( 16 ) :5367-5374.
  • 6Bartek J, Iggo R, Gaannon J, et al. Genetic and immunochemicalanaly- sis of mutant P53 in human breast cancer ceil line [ J ]. Oncogene, 1990,5 (6) :893-899.
  • 7Norberg T, Klaar S, Karl" G, et al. Increased P53 mutation frequen- cyduring tumor progression-resuh from a breast cancer cohort [ J ]. Cancer Res ,2001,61 (22) :8317-8321.
  • 8Soussi T, Brroud C. A ssessin TP 53 status in human tumours to evalu- ate clinical outcome[ J ]. Nat Rev Cancer,200] , 1 (3) :233-240.
  • 9Turnrt N, Moretti E, Sielari O, et al. Targeting triple negative breast cancer:Is p53 the answer [ J ]Cancer Treatment Reviews, 2013,39 ( 5 ) :541-550.
  • 10Nishimura R, Arima N. Is triple negative a prognosis factor in breast cancer [ J ]. Breast cancer,2008,15 (4) :303-308.

引证文献7

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部